Published in Vaccine Weekly, June 29th, 2011
"A number of serious bacterial diseases still lack vaccines while antibiotic resistance is growing and the costs for vaccines development is increasing," said Philippe Dro, CEO of GlycoVaxyn. "Setbacks in vaccine development, most recently with Staphylococcus aureus, highlight the challenges facing the vaccine industry and public health professionals. Our science day provides a forum for industry, regulatory and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly